Hyundai Bioscience Co (XKRX:048410) Cash-to-Debt : 0.70 (As of Mar. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Hyundai Bioscience Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.70.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Hyundai Bioscience Co couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Hyundai Bioscience Co's Cash-to-Debt or its related term are showing as below:

XKRX:048410' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31 Med: 0.67 Max: 3.51
Current: 0.7

During the past 13 years, Hyundai Bioscience Co's highest Cash to Debt Ratio was 3.51. The lowest was 0.31. And the median was 0.67.

XKRX:048410's Cash-to-Debt is ranked worse than
81.41% of 1522 companies
in the Biotechnology industry
Industry Median: 6.235 vs XKRX:048410: 0.70

Hyundai Bioscience Co Cash-to-Debt Historical Data

The historical data trend for Hyundai Bioscience Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Hyundai Bioscience Co Cash-to-Debt Chart

Hyundai Bioscience Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.52

1.43

3.00

2.13

Hyundai Bioscience Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															2.68	2.79	2.24	2.13	0.70

Competitive Comparison of Hyundai Bioscience Co's Cash-to-Debt

For the Biotechnology subindustry, Hyundai Bioscience Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyundai Bioscience Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyundai Bioscience Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Hyundai Bioscience Co's Cash-to-Debt falls into.

Hyundai Bioscience Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Hyundai Bioscience Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11811.88	/	(5514.103	+	32.432)
	=	2.13

Hyundai Bioscience Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3864.544	/	(5509.538	+	24.159)
	=	0.70

Hyundai Bioscience Co (XKRX:048410) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Hyundai Bioscience Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Hyundai Bioscience Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyundai Bioscience Co (XKRX:048410) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR

Website

http://www.hyundaibioscience.com

Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co (XKRX:048410) Headlines

No Headlines